COMP <GO>
BLLN vs ABBV // RSI-14 & 200D SMA MOMENTUM
BillionToOne Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BLLN 4
— ABBV 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $113.32 (-1.32%) • MKT CAP: $5.42B
rsi-technicals
59.5
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BLLN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BLLN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 68.30% | 70.20% | -1.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.90% | 29.00% | -26.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 33.3x | +61.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 0.29% | 3.47% | -3.18 | ABBV | /fcf-yield <GO> |
| Operating Margin | 5.30% | 24.60% | -19.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 6.90% | -4.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 100.00% | 8.60% | +91.40 | BLLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.24 | 5.33 | +16.91 | BLLN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | BLLN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.40% | -0.40 | BLLN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 59.5 | 72.8 | -13.30 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.15 | -0.13 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 113.1x | +26.90 | ABBV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.42B | $513.86B | -$508.44B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BLLN REV | ABBV REV | BLLN GROSS % | ABBV GROSS % | BLLN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $305.1M | $61.16B | 68.3% | 70.2% | $15.7M | $17.82B |
| FY 2024 | $152.6M | $56.33B | 53.0% | 70.0% | -$46.8M | $17.83B |
| FY 2023 | $71.7M | $54.32B | 44.0% | 44.0% | -$56.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BLLN // BETA 1.02
ABBV // BETA 1.15